Mark J Ratain MD

PubMed

• Missed Opportunity for Sotorasib Dose Optimization.
  Garth W Strohbehn, Jill Feldman, Sanjay Popat, Mark J Ratain
  Journal of Clinical Oncology. 2025-04-20
• Triaging Acute Chest Syndrome Clinical Decision-Making Using Bedside SaO2/FiO2 Ratio.
  Austin Wesevich, Megan Elizabeth Woelkers, Ayodeji Adegunsoye, Adam J Wesevich, Mark J Ratain
  Blood Advances. 2025-04-03
• Formulation-Based Cost Savings with Cabozantinib Capsules.
  Austin Wesevich, Walter M Stadler, Mark J Ratain
  JAMA Oncology. 2025-04-03

Journal Articles

• Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19  
  Mark J Ratain, Leonard B Saltz, JAMA Oncology
• A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer Using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance)  
  Hope S Rugo, Francisco Castillos, Beth Overmoyer, Mark J Ratain, Clinical Pharmacology & Therapeutics
• A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469  
  Ramirez J, Kim TW, Liu W, Myers JL, Mirkov S, Owzar K, Watson D, Mulkey F, Gamazon ER, Stock W, Undevia S, Innocenti F, Ratain MJ, Pharmacogenet Genomics, 1/1/2014
• The relationship of polymorphisms in ABCC2 and SLCO1B3 to docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance)  
  Lewis LD, Miller AA, Owzar K, Bies RR, Markova S, Jiang C, Kroetz DL, Egorin MJ, McLeod HL, Ratain MJ, Pharmacogenet Genomics, 1/1/2013
• Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of paclitaxel-induced sensory neuropathy  
  Wheeler HE, Gamazon ER, Wing C, Njaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman L, Ratain MJ, Kro..., Clin Cancer Res, 1/1/2013
• Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression  
  Nguyen TD, Markova S, Liu W, Gow JM, Baldwin RM, Habashian M, Relling MV, Ratain MJ, Kroetz DL, Pharmacogenomics, 1/1/2013
• Estimation of renal cell carcinoma treatment effects from disease progression modeling  
  Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, Stadler WM, Karrison TG, Ratain MJ, Bies RR, Pharmacol Ther, 1/1/2013
• Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients  
  Wang LZ, Ramírez J, Yeo W, Chan MY, Thuya WL, Lau JY, Wan SC, Wong AL, Zee YK, Lim R, Lee SC, Ho PC, Lee HS, Chan A, Ansher S, Ratain MJ, Goh BC, PLoS ONE, 1/1/2013
• Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients  
  Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE, Clin Cancer Res, 1/1/2013
• Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751  
  Innocenti F, Ramírez J, Obel J, Xiong J, Mirkov S, Chiu YL, Katz DA, Carr RA, Zhang W, Das S, Adjei A, Moyer AM, Chen PX, Krivoshik A, Medina D, Gordon GB, Ratain MJ, ..., Pharmacogenet Genomics, 1/1/2013
• A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection  
  Kitano S, Myers J, Nakamura J, Yamane A, Yamashita M, Nakayama M, Tsukahara Y, Ushida H, Liu W, Ratain MJ, Amano M, PLoS ONE, 1/1/2013
• A genome-wide integrative study of microRNAs in liver  
  Gamazon ER, Innocenti F, Wei R, Wang L, Zhang M, Mirkov S, Ramirez J, Huang RS, Cox NJ, Ratain MJ, Liu W, BMC Genomics, 1/1/2013
• Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis  
  Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen EEW, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, Maitland ML, Oncologist, 1/1/2013
• Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter OCT1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene  
  O’Brien VP, Bokelmann K, Ramirez J, Jobst K, Ratain MJ, Brockmoller J, Tzvetkov MV, J Pharmacol Exp Ther, 1/1/2013
• Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs  
  Wu K, House L, Ramirez J, Seminerio MJ, Ratain MJ, Clin Cancer Res, 1/1/2013
• Germline variants and advanced colorectal adenomas: Adenoma Prevention with Celecoxib Prevention Trial genomewide association study  
  Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG, Collaborators AT, Kubo M, Matsuda K, Dunlop M, Houlston RS, Sieber OM, Lipton L, Gibbs P, Martin NG, Montgomery GW, You..., Clin Cancer Res, 1/1/2013
• Preventing adverse drug-drug interactions: a need for improved data and logistics  
  Seminerio MJ, Ratain MJ, Mayo Clin Proc, 1/1/2013
• Time to tumor growth: a model endpoint and new metric system for oncology clinical trials  
  Maitland ML, Schwartz LH, Ratain MJ, J Clin Oncol, 1/1/2013
• CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality  
  Ratain MJ, Nakamura Y, Cox NJ, Clin Pharmacol Ther, 1/1/2013
• Are drug labels static or dynamic?  
  Seminerio MJ, Ratain MJ, Clin Pharmacol Ther, 1/1/2013
• Tumour heterogeneity in the clinic  
  Bedard PL, Hansen AR, Ratain MJ, Siu LL, Nature, 1/1/2013
• University of Chicago Center for Personalized Therapeutics: research, education and implementation science  
  Dolan ME, Maitland ML, O’Donnell PH, Nakamura Y, Cox NJ, Ratain MJ, Pharmacogenomics, 1/1/2013
• Challenges in interpreting the evidence for genetic predictors of ototoxicity  
  Ratain MJ, Cox NJ, Henderson TO, Clin Pharmacol Ther, 1/1/2013
• Unmet needs in preventing adverse drug-drug interactions  
  Ratain MJ, Seminerio MJ, Clin Adv Hematol Oncol, 1/1/2013
• Resampling phase III data to assess phase II trial designs and endpoints  
  Sharma MR, Karrison TG, Jin Y, Bies RR, Maitland ML, Stadler WM, Ratain MJ, Clin Cancer Res, 1/1/2012
• Join now to see all

Lectures

• Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621. 
  2019 ASCO Annual Meeting - 6/1/2019